<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="58784"><DrugName>pegunigalsidase alfa</DrugName><DrugNamesKey><Name id="43085355">pegunigalsidase alfa</Name></DrugNamesKey><DrugSynonyms><Name><Value>galactosidase enzyme replacement therapy (Fabry disease), Protalix</Value></Name><Name><Value>pegunigalsidase alfa</Value><Types><Type>INN</Type></Types></Name><Name><Value>PRX-102</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>recombinant human alpha galactosidase-A</Value></Name><Name><Value>galactosidase enzyme replacement therapy (Fabry disease), Protalix/Chiesi Farmaceutici</Value></Name></DrugSynonyms><CompanyOriginator id="1014359">Protalix BioTherapeutics Inc</CompanyOriginator><CompaniesPrimary><Company id="15381">Chiesi Farmaceutici SpA</Company></CompaniesPrimary><CompaniesSecondary><Company id="1014359">Protalix BioTherapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="58784" type="Drug"><TargetEntity id="459818" type="siDrug">Pegunigalsidase alfa</TargetEntity></SourceEntity><SourceEntity id="1014359" type="Company"><TargetEntity id="4295899881" type="organizationId">Protalix Biotherapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="15381" type="Company"><TargetEntity id="4296558863" type="organizationId">Chiesi Farmaceutici SpA</TargetEntity></SourceEntity><SourceEntity id="774" type="ciIndication"><TargetEntity id="E75.21" type="ICD10"></TargetEntity><TargetEntity id="10016016" type="MEDDRA"></TargetEntity><TargetEntity id="D000795" type="MeSH"></TargetEntity><TargetEntity id="324" type="ORPHANET"></TargetEntity><TargetEntity id="-1847291444" type="omicsDisease"></TargetEntity><TargetEntity id="979" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00119" type="ciTarget"><TargetEntity id="56651435227173" type="siTarget">Alpha-galactosidase A</TargetEntity><TargetEntity id="-1101459958" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="774">Fabry disease</Indication></IndicationsPrimary><ActionsPrimary><Action id="7147">Alpha-galactosidase stimulator</Action></ActionsPrimary><Technologies><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="901">Recombinant enzyme</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2019-07-01T11:27:31.000Z</LastModificationDate><ChangeDateLast>2019-06-18T00:00:00.000Z</ChangeDateLast><AddedDate>2007-11-26T09:55:34.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15381" linkType="Company"&gt;Chiesi Farmaceutici&lt;/ulink&gt;,  under license from  &lt;ulink linkID="1014359" linkType="Company"&gt;Protalix BioTherapeutics&lt;/ulink&gt;,   is developing pegunigalsidase alfa (PRX-102), an enzyme replacement therapy that uses chemically modified recombinant human alpha galactosidase produced by the company's  ProCellEx plant cell expression system, for the potential iv treatment of Fabry disease [&lt;ulink linkID="889818" linkType="Reference"&gt;889818&lt;/ulink&gt;], [&lt;ulink linkID="1348743" linkType="Reference"&gt;1348743&lt;/ulink&gt;], [&lt;ulink linkID="1879431" linkType="Reference"&gt;1879431&lt;/ulink&gt;], [&lt;ulink linkID="1972338" linkType="Reference"&gt;1972338&lt;/ulink&gt;].     &lt;/para&gt;&lt;para&gt;In June 2016, a phase III trial (BALANCE) of the drug given every 2 weeks began in Fabry patients with impaired renal function previously treated with &lt;ulink linkID="11205" linkType="Drug"&gt;agalsidase beta&lt;/ulink&gt;  [&lt;ulink linkID="1769708" linkType="Reference"&gt;1769708&lt;/ulink&gt;]; in August 2017, initial data demonstrated tolerability [&lt;ulink linkID="1952240" linkType="Reference"&gt;1952240&lt;/ulink&gt;]; in June 2019, the trial was ongoing [&lt;ulink linkID="2160319" linkType="Reference"&gt;2160319&lt;/ulink&gt;].  In June 2017, a supportive phase III study (BRIDGE) began in Fabry patients previously  treated with &lt;ulink linkID="14366" linkType="Drug"&gt;agalsidase alfa&lt;/ulink&gt;  and on a stable dose   [&lt;ulink linkID="1902432" linkType="Reference"&gt;1902432&lt;/ulink&gt;]; in September 2018, positive preliminary data  were reported [&lt;ulink linkID="2074926" linkType="Reference"&gt;2074926&lt;/ulink&gt;]; in June 2019, the trial was ongoing [&lt;ulink linkID="2160319" linkType="Reference"&gt;2160319&lt;/ulink&gt;]. In September 2017, a phase III  switchover trial (BRIGHT) commenced in Fabry patients previously been treated with agalsidase beta or agalsidase alfa   [&lt;ulink linkID="1945568" linkType="Reference"&gt;1945568&lt;/ulink&gt;]; in February 2019, positive preliminary pharmacokinetic data were reported  [&lt;ulink linkID="2117029" linkType="Reference"&gt;2117029&lt;/ulink&gt;]. In June 2019, following a series of meetings and correspondence with the FDA, a BLA filing  was expected to be submitted in 1Q20 via the accelerated approval pathway [&lt;ulink linkID="2160319" linkType="Reference"&gt;2160319&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Product patent &lt;ulink linkID="PA6523454" linkType="Patent"&gt;US-08449876&lt;/ulink&gt; provides protection until February 2024. In  March 2018, Protalix stated that US and international composition of matter patents for the drug had been filed. Additionally, the company   expected,  subject to EU approval of the drug and EU Orphan designation maintenance, 10 years of market exclusivity in the EU   [&lt;ulink linkID="2011758" linkType="Reference"&gt;2011758&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The U	S&lt;/subtitle&gt;In December 2018, the company planned to meet with the US FDA to discuss the optimal regulatory pathway for PRX-102 in  1Q19; at that time, the company planned to file with accelerated approval [&lt;ulink linkID="2104877" linkType="Reference"&gt;2104877&lt;/ulink&gt;]; in March 2019, the company reported that a Type C meeting  was to be held by the end of 2Q19 to discuss a potential filing for accelerated approval [&lt;ulink linkID="2130895" linkType="Reference"&gt;2130895&lt;/ulink&gt;]. In June 2019, following a series of meetings and correspondence with the FDA, a BLA filing (based on completed phase I/II clinical trials and from the ongoing phase III BRIDGE clinical trial) was expected to be submitted in 1Q20 via the accelerated approval pathway [&lt;ulink linkID="2160319" linkType="Reference"&gt;2160319&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2018, the US FDA  granted Fast Track designation to pegunigalsidase alfa for the treatment of Fabry disease [&lt;ulink linkID="2001494" linkType="Reference"&gt;2001494&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2015, following an end-of-phase II meeting, the FDA  accepted the company's phase III plan to support BLA submission  [&lt;ulink linkID="1713795" linkType="Reference"&gt;1713795&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2017, the EMA's COMP issued a positive opinion on granting Orphan designation for pegunigalsidase alfa for the treatment of Fabry disease [&lt;ulink linkID="1989960" linkType="Reference"&gt;1989960&lt;/ulink&gt;], [&lt;ulink linkID="1987727" linkType="Reference"&gt;1987727&lt;/ulink&gt;]; in December 2017, pegunigalsidase alfa was granted Orphan drug designation for the treatment of Fabry disease by the EC [&lt;ulink linkID="1993871" linkType="Reference"&gt;1993871&lt;/ulink&gt;], [&lt;ulink linkID="2003023" linkType="Reference"&gt;2003023&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In November 2018, an open-label extension,  single group assignment, interventional phase III trial (&lt;ulink linkID="348742" linkType="Protocol"&gt;NCT03614234&lt;/ulink&gt;; PB-102-F51) was initiated in the US, Belgium and Norway in patients (expected  n = 40) with  Fabry disease  to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alfa. The primary outcome was  evaluation of treatment-related adverse events. At that time, the trial was expected to complete in January 2022 [&lt;ulink linkID="2112943" linkType="Reference"&gt;2112943&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2017, the company had received IND approval to initiate an open-label, switchover, phase III trial (&lt;ulink linkID="300965" linkType="Protocol"&gt;NCT03180840&lt;/ulink&gt;; PB-102-F50; BRIGHT) in the US, Canada and the UK to assess the safety and efficacy of pegunigalsidase alfa administered once a month (2mg/kg) over 52 weeks in Fabry patients (expected n = 30) who had previously been treated with &lt;ulink linkID="11205" linkType="Drug"&gt;agalsidase beta&lt;/ulink&gt; or &lt;ulink linkID="14366" linkType="Drug"&gt;agalsidase alfa&lt;/ulink&gt; for at least 3 years. At that time, the trial was expected to complete in December 2019. In September 2017, the trial commenced  [&lt;ulink linkID="1926438" linkType="Reference"&gt;1926438&lt;/ulink&gt;], [&lt;ulink linkID="1945568" linkType="Reference"&gt;1945568&lt;/ulink&gt;]. In September 2017, the trial commenced in the US,   Canada and Europe [&lt;ulink linkID="1945568" linkType="Reference"&gt;1945568&lt;/ulink&gt;]. In March 2018, trial enrollment was expected to complete later that year and a safety and efficacy evaluation was to occur at 12 months with additional long term follow-up [&lt;ulink linkID="2011008" linkType="Reference"&gt;2011008&lt;/ulink&gt;], [&lt;ulink linkID="2011758" linkType="Reference"&gt;2011758&lt;/ulink&gt;]. In July 2018, data were expected for 1H19 [&lt;ulink linkID="2056785" linkType="Reference"&gt;2056785&lt;/ulink&gt;].  In December 2018, the study was approximately 90% enrolled [&lt;ulink linkID="2104877" linkType="Reference"&gt;2104877&lt;/ulink&gt;]; later that month,  28 patients  had been enrolled [&lt;ulink linkID="2117029" linkType="Reference"&gt;2117029&lt;/ulink&gt;]. In February 2019, preliminary pharmacokinetic data from 15 patients who had completed 9 months of treatment in the switchover study were presented at the 15th Annual Lysosomal Disease Network  Annual WORLDSymposium 2019 in Orlando, FL. Results demonstrated that pegunigalsidase alfa was present and remained active in  plasma over the 4-week infusion intervals, with a  mean concentration at day 28 of 138 ng/ml compared with 20 ng/ml at 10-h post infusion in published data for  agalsidase beta (1mg/kg every 2 weeks). The AUC value  for pegunigalsidase alfa was approximately 2,000,000 ng/h/ml over 28 days compared with approximately 10,000 ng/h/ml in published data for  agalsidase beta. Additionally, pre-existing anti-drug antibodies (ADAs) generated in patients prior to switching  had  little effect on the circulation of pegunigalsidase alfa for the 4-week period evaluated, and pegunigalsidase alfa concentration in circulation was higher than agalsidase beta, even in the presence of ADAs. Data from a  preliminary safety analysis of 19 patients  indicated that the drug was safe and well tolerated [&lt;ulink linkID="2117029" linkType="Reference"&gt;2117029&lt;/ulink&gt;]. At the same conference, interim results were presented.  From the first 15 patients, preliminary pharmacokinetic results showed a half-life of approximately 80 h and persistent plasma levels over the entire 4-week dosing interval, with a mean concentration on day 28 post-infusion of 138 ng/ml. The AUC0-28 days was 2,126,091 ng.h/ml, of which the mean partial AUC during the fourth week was approximately 30,000 ng.h/ml [&lt;ulink linkID="2118957" linkType="Reference"&gt;2118957&lt;/ulink&gt;]. In March 2019, all of the 13 patients that have completed the 12-month study have opted,  to continue with once-monthly dosing in an extension study rather than switching back to the 1mg/kg every two weeks regimen [&lt;ulink linkID="2130895" linkType="Reference"&gt;2130895&lt;/ulink&gt;]. In May 2019, the trial was one patient away from the completion of the enrollment [&lt;ulink linkID="2148339" linkType="Reference"&gt;2148339&lt;/ulink&gt;]. In June 2019, enrollment was completed [&lt;ulink linkID="2165062" linkType="Reference"&gt;2165062&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2017, an interventional, open-label,  single-group assigned, switch-over, phase III study (&lt;ulink linkID="284998" linkType="Protocol"&gt;NCT03018730&lt;/ulink&gt;; PB-102-F30; BRIDGE) was planned in patients with Fabry disease (expected n = 22) to evaluate the safety and efficacy of pegunigalsidase alfa. Patients would have previously been treated with &lt;ulink linkID="14366" linkType="Drug"&gt;agalsidase alfa&lt;/ulink&gt; for at least 2 years and on a stable dose for at least 6 months. Following a screening and evaluation period over 3 months while continuing on agalsidase alfa, subjects would be switched to pegunigalsidase alfa. In June 2017, the trial was initiated in Australia, Canada, Czech Republic, Germany, the Netherlands, Norway, Spain and the UK [&lt;ulink linkID="1902432" linkType="Reference"&gt;1902432&lt;/ulink&gt;]. In September 2018, preliminary data from the first 16 patients were reported, showing that a trend towards deterioration in kidney function in patients receiving agalsidase alfa (estimated glomerular filtration rate (eGFR) slope of -6.8ml/min/1.73m2) was reversed to an improvement trend when patients were switched to pegunigalsidase alfa (eGFR slope of +3.7ml/min/1.73m2) [&lt;ulink linkID="2074926" linkType="Reference"&gt;2074926&lt;/ulink&gt;].  Later that month, similar data from 22 patients were presented at the Canadian Symposium on Lysosomal Diseases 2018 in Quebec, CA. At that time, patient enrollment was expected to complete in 4Q18  [&lt;ulink linkID="2079939" linkType="Reference"&gt;2079939&lt;/ulink&gt;]. In December 2018, enrollment was completed [&lt;ulink linkID="2104877" linkType="Reference"&gt;2104877&lt;/ulink&gt;].  In February 2019, further data were presented at the 15th Annual Lysosomal Disease Network WORLD Symposium in Orlando, FL. Within 6 months of treatment, mean annualized eGFR slope was changed from -6.8 ml/min/1.73m2/year with agalsidase alfa to +3.7 ml/min/1.73m2/year with pegunigalsidase alfa in first 16 patients [&lt;ulink linkID="2118996" linkType="Reference"&gt;2118996&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2016, a randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="273893" linkType="Protocol"&gt;NCT02921620&lt;/ulink&gt;; PB-102-F10) was planned to assess the safety and efficacy of pegunigalsidase alfa on gastrointestinal symptoms in ERT naive male Fabry disease patients aged 14 to 45 years old (n = 38). Subjects would receive 1 mg/kg of the drug or placebo once every 2 weeks over a period of 6 months. At that time, the trial was expected to begin in July 2017 and complete in July 2018 [&lt;ulink linkID="1945570" linkType="Reference"&gt;1945570&lt;/ulink&gt;]. In March 2018, trial enrollment was expected to complete later that year [&lt;ulink linkID="2011008" linkType="Reference"&gt;2011008&lt;/ulink&gt;]. In July 2018, data were expected for 1H19 [&lt;ulink linkID="2056785" linkType="Reference"&gt;2056785&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, the company received an acceptance from the  FDA for a randomized, multicenter, placebo-controlled, phase III  trial in patients with Fabry disease to assess the safety and efficacy  of pegunigalsidase alfa compared with Fabrazyme  [&lt;ulink linkID="1713795" linkType="Reference"&gt;1713795&lt;/ulink&gt;].   By May 2016, an SPA had been submitted for Fabry disease  [&lt;ulink linkID="1760353" linkType="Reference"&gt;1760353&lt;/ulink&gt;]. In June 2016, the randomized, double-blind, active-controlled, phase III trial (&lt;ulink linkID="262822" linkType="Protocol"&gt;NCT02795676&lt;/ulink&gt;; B-102-F20; BALANCE) was initiated in the US, Australia, Canada, Europe, and Paraguay   [&lt;ulink linkID="1769708" linkType="Reference"&gt;1769708&lt;/ulink&gt;], [&lt;ulink linkID="1879431" linkType="Reference"&gt;1879431&lt;/ulink&gt;]. At that time, the company intended to conduct an interim analysis to test for non-inferiority to support an anticipated regulatory filing with the EMA at 12 months [&lt;ulink linkID="1769708" linkType="Reference"&gt;1769708&lt;/ulink&gt;]. In October 2016, the first patient was dosed in the 24-month  trial [&lt;ulink linkID="1866562" linkType="Reference"&gt;1866562&lt;/ulink&gt;]. The trial would investigate safety and efficacy compared with &lt;ulink linkID="11205" linkType="Drug"&gt;agalsidase beta&lt;/ulink&gt; (Fabrazyme) in patients (estimated n = 78) with Fabry disease with impaired renal function previously treated with agalsidase beta  [&lt;ulink linkID="1866562" linkType="Reference"&gt;1866562&lt;/ulink&gt;],  [&lt;ulink linkID="1879431" linkType="Reference"&gt;1879431&lt;/ulink&gt;]. In October 2016, the study was expected to complete in June 2019 [&lt;ulink linkID="1879431" linkType="Reference"&gt;1879431&lt;/ulink&gt;]. In August 2017, initial data demonstrated tolerability [&lt;ulink linkID="1952240" linkType="Reference"&gt;1952240&lt;/ulink&gt;]. In January 2018, enrollment was ongoing [&lt;ulink linkID="2001494" linkType="Reference"&gt;2001494&lt;/ulink&gt;]. In March 2018, trial enrollment was expected to complete later that year [&lt;ulink linkID="2011008" linkType="Reference"&gt;2011008&lt;/ulink&gt;]. In May 2018, data as of January 2018 from the first 37 patients (27 males, 10 females) were presented at the 55th ERA-EDTA Congress in Copenhagen, Denmark. Screening of the patients revealed 15 out of 27 male patients were anti-drug antibody-positive. Of those, all 15 had neutralizing antibodies to Fabrazyme and 14 out of the 15 also had neutralizing activity toward pegunigalsidase alfa as part as ex-vivo immunogenicity testing. Titers measured in ADA against Fabrazyme were higher by an average of more than 2-fold compared with those measured against pegunigalsidase alfa.  Additionally, Fabrazyme was inhibited by an average of 83.6% leaving only 16.4% of effective enzyme, while pegunigalsidase alfa was inhibited by 61.6%, leaving 38.4% of effective enzyme.  No ADAs were pbserved in the 10 female patients. The average annualized estimated Glomerular filtration rate (eGFR) slope for the 15 male patients that tested positive for ADA was -7.9 (SD=6.0) ml/min/1.73m2/year which showed   a progressive decline in kidney function, despite being treated with Fabrazyme for 1 to 12 years. At that time, 60 patients had been screened for the study, including the 37 patients analyzed for the presentation [&lt;ulink linkID="2037711" linkType="Reference"&gt;2037711&lt;/ulink&gt;]. In December 2018, the study was approximately 70% enrolled [&lt;ulink linkID="2104877" linkType="Reference"&gt;2104877&lt;/ulink&gt;]. In February 2019, data were presented at the 15th Annual Lysosomal Disease Network WORLD Symposium in Orlando, FL. Switching from a long-term standing treatment with agalsidase beta to pegunigalsidase alfa with lower enzyme activity inhibition combined with approximately 40-fold longer plasma half-life, resulted in higher amount of effective enzyme available in the circulation of patients. In 64% of ADA-positive FD male patients, a significant proteinuria levels (urine protein/creatinine ratio &amp;gt;/- 500 mg/gr) were observed [&lt;ulink linkID="2118988" linkType="Reference"&gt;2118988&lt;/ulink&gt;]. In March 2019, the study was  80% enrolled [&lt;ulink linkID="2130895" linkType="Reference"&gt;2130895&lt;/ulink&gt;]. In May 2019, a total of 11 patients were to be enrolled in the trial  from completion of enrollment [&lt;ulink linkID="2148339" linkType="Reference"&gt;2148339&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In  December 2010, a pre-IND meeting was held with the FDA [&lt;ulink linkID="1271113" linkType="Reference"&gt;1271113&lt;/ulink&gt;]. In January 2011, the company planned to file an IND later that year to initiate a phase I/II trial [&lt;ulink linkID="1161905" linkType="Reference"&gt;1161905&lt;/ulink&gt;]. In August 2012, the FDA granted the IND application to initiate the 12-week, multicenter, open-label, dose ranging, safety, tolerability, pharmacokinetic and efficacy trial in patients (expected n = 18) with Fabry's disease. After the trial completion, the company intended to offer the patients to continue in an open-label extension study [&lt;ulink linkID="1315120" linkType="Reference"&gt;1315120&lt;/ulink&gt;]. In October 2012, the non-randomized phase I/II trial (&lt;ulink linkID="90840" linkType="Protocol"&gt;NCT01678898&lt;/ulink&gt;; PB-102-F01) was initiated [&lt;ulink linkID="1329252" linkType="Reference"&gt;1329252&lt;/ulink&gt;]; in December 2012, the first patient was treated in the worldwide trial [&lt;ulink linkID="1348743" linkType="Reference"&gt;1348743&lt;/ulink&gt;].   In January 2015, positive interim data were reported from 12 patients (6 patients enrolled in the 0.2mg/kg dose group and 6 patients enrolled in the 1mg/kg dose group). Data demonstrated that the drug resulted in Gb3 reductions in renal peritubular capillaries, significant improvements in pain parameters, cardiac and kidney function stabilization, and low level of antibody formation and the drug was found to be well tolerated. At that time,  enrollment was expected to be completed by the end of first quarter of 2015 [&lt;ulink linkID="1625152" linkType="Reference"&gt;1625152&lt;/ulink&gt;]. In February 2015, patient enrollment was completed and all the patients opted to continue to receive pegunigalsidase alfa in an open-label extension trial (&lt;ulink linkID="104903" linkType="Protocol"&gt;NCT01769001&lt;/ulink&gt;; PB-102-F02) [&lt;ulink linkID="1630631" linkType="Reference"&gt;1630631&lt;/ulink&gt;]; later that month, additional positive interim data from 18 patients (6 patients enrolled in the 0.2mg/kg dose group and 6 patients enrolled in the 1mg/kg dose group) were  presented  at the  Lysosomal Disease Network WORLD Symposium in Orlando, FL.  The cardiac and kidney functions were measured by mean left ventricular mass (LVM), left ventricular mass index (LVMI), ejection fraction (EF), eGFR and urine protein. A favourable trend was observed for both the functions. Pegunigalsidase alfa  showed a major reduction  of  82.2, 65.4  and 75.5% with an absolute change of -4.5, -1.2 and -3.2, respectively, in renal peritubular capillary Gb for  males, females and both, respectively from baseline. Also, a reduction of 69.6, 100, 60 and 100% in abnormal capillary score, pain, mean severity and  mean interference was found.   The mean change of -2.4 nanog/mL and   -0.4 microg/mL  for females (n=2)   and  -96.2 nanog/mL and a -1.3 microg/mL for males (n=4) were showed in Lyso-Gb3 and plasma Gb3 concentrations, respectively. Out of 8 patients receiving a dose of 0.2 (n=6) and  1mg/kg (n=2)  who were evaluated for ADA formation, 2 patients developed ADA in the 0.2mg/kg cohort. The drug was found to be safe, effective and well tolerated [&lt;ulink linkID="1633535" linkType="Reference"&gt;1633535&lt;/ulink&gt;], [&lt;ulink linkID="1633645" linkType="Reference"&gt;1633645&lt;/ulink&gt;]. In September 2015, positive interim data from 6 patients in the 1mg/kg dose group were reported.  Pegunigalsidase alfa showed a major reduction  of 86% in renal peritubular capillary. The mean change of -9.2 nanog/mL and   -0.23 microg/mL  for females (n = 2)   and  -67.5 nanog/mL and a -5.3 microg/mL for males (n=4) were showed in Lyso-Gb3 and plasma Gb3 concentrations, respectively. All patients had stable cardiac function after only six months. Pegunigalsidase alfa was found to be well tolerated. At that time, longer term data from the first 0.2mg/kg cohort  and  full top-line results from all dosing cohorts were expected by the end of  September  2015 and  in the fourth quarter of 2015, respectively  [&lt;ulink linkID="1693165" linkType="Reference"&gt;1693165&lt;/ulink&gt;]. In October 2015, positive long term data were reported. Data demonstrated that a majority of the patients (4/6) experienced a stabilization or improvement in kidney function and a reversal of the decline shown by annualized eGFR slope was observed. In addition, Fabry patients of the 0.2mg/kg cohort  showed a continuous reduction and durable improvement in Mainz Severity Score Index (MSSI). Improved PK profile including long half-life, high AUC and measured levels of enzyme was found throughout the entire two weeks infusion intervals in all patients of the 0.2mg/kg cohort. Mean values for Cmax, and AUC were found to have briefly shifted at three and six months in antibody positive patients, where at 12 months, PK parameters returned to the high AUC levels observed at baseline  [&lt;ulink linkID="1704499" linkType="Reference"&gt;1704499&lt;/ulink&gt;]. In March 2016, positive interim data were presented at the 12th Annual World Symposium in San Diego, CA. Data demonstrated that pegunigalsidase alfa 	showed an overall reduction of 75.5 and 86.5% Gb3 in the 0.2 and 1.0 mg/kg dosing cohorts and the annualized eGFR slope for male patients was found to be 0.16 and 0.72 for the 0.2 and 1.0 mg/kg doses, respectively. The drug was safe and well-tolerated [&lt;ulink linkID="1740146" linkType="Reference"&gt;1740146&lt;/ulink&gt;], [&lt;ulink linkID="1747261" linkType="Reference"&gt;1747261&lt;/ulink&gt;]. In August 2016, additional positive data were reported. Improvements or stabilization in efficacy were demonstrated across all disease parameters. The kidney and cardiac functions    were stable. The reductions of plasma Lyso-Gb3 ranged from 66.7 to 22.6 ng/ml in all patients and from 102.0 to 33.1 ng/ml in classic patients. The program  was found to be safe [&lt;ulink linkID="1787243" linkType="Reference"&gt;1787243&lt;/ulink&gt;]. In September 2016, results were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Rome, Italy [&lt;ulink linkID="1794457" linkType="Reference"&gt;1794457&lt;/ulink&gt;]. In February 2017, data were presented at the 13th Annual Lysosomal Disease Network WORLD Symposium in San Diego, CA. In cohort 1 and 2, treatment induced IgG antibodies to PRX-102 (ADA+) was developed in two and one patients, respectively; while in cohort 3, no ADA+ patients were observed. In two ADA+ patients from cohort 1, compared to Day 1, a distinct and reversible effect on PK profile was observed at 3 and 6 months which resulted in decreased Cmax and AUC; and after 12 months of treatment, the PK profile improved back to baseline which suggested that ADA had a transient impact of on PRX-102 activity [&lt;ulink linkID="1901581" linkType="Reference"&gt;1901581&lt;/ulink&gt;]. Further one-year follow-up data from ten classic Fabry disease patients were presented at the same conference. With all three doses after one year of treatment, classic FD patients showed mean total reduction of Gb3 inclusion in peri-tubular capillary endothelial cells of 84.1% (Barisoni lipid inclusion scoring system score); mean reduction in plasma Gb3 and Lyso Gb3 of 33.3 and 57.6%. Annualized estimated glomerular filtration rate and cardiac MRI were stabilized, and Mainz severity score index and brief pain inventory scores were improved [&lt;ulink linkID="1901621" linkType="Reference"&gt;1901621&lt;/ulink&gt;]. In September 2017, similar data were presented at the 13th ICIEM in Rio de Janeiro, Brazil.Similar data were presented at the same conference [&lt;ulink linkID="1966169" linkType="Reference"&gt;1966169&lt;/ulink&gt;]. In November 2017, 2-year data  from 11 patients in the long-term open-label extension trial were presented at the New Horizons in Fabry Disease Conference in Prague, Czech Republic. At 24 months, treatment with pegunigalsidase alfa resulted in a 90% reduction in Lyso Gb3 levels from baseline, and renal function remained stable with mean eGRF levels of 108.02 and 107.20 at baseline and 24 months, respectively. Additionally, an improvement across all the gastrointestinal symptoms evaluated and cardiac parameters remained stable [&lt;ulink linkID="1985637" linkType="Reference"&gt;1985637&lt;/ulink&gt;]. In February 2018, further data were presented at the 14th Annual Lysosomal Disease Network WORLD Symposium in San Diego, CA. At 24 months, Mainz Severity Score Index and biomarkers were improved [&lt;ulink linkID="2009552" linkType="Reference"&gt;2009552&lt;/ulink&gt;]. In March 2018, the extension period of the trial was ongoing [&lt;ulink linkID="2011758" linkType="Reference"&gt;2011758&lt;/ulink&gt;]. By February 2019, data from the phase I/II trial were reported. The drug demonstrated  a circulatory  half-life of approximately 80h   [&lt;ulink linkID="2118586" linkType="Reference"&gt;2118586&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2018, an in vitro analysis was presented at the Canadian Symposium on Lysosomal Diseases 2018 in Quebec, CA, which showed that for pegunigalsidase alfa 84% of its activity was preserved in lysosomal-like conditions after 10 days, compared with approximately 1% remaining enzyme activity in each of the commercially available ERTs (p = 0.01) [&lt;ulink linkID="2079939" linkType="Reference"&gt;2079939&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, preclinical data were presented at the 13th ICIEM in Rio de Janeiro, Brazil. Pegunigalsidase alfa exhibited prolonged in-vitro stability in plasma and under lysosomal-like conditions. In male Fabry mice, pegunigalsidase alfa exhibited t1/2 of 581 min [&lt;ulink linkID="1966165" linkType="Reference"&gt;1966165&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. In 2 months old Fabry mice, treatment with pegunigalsidase alfa (1 mg/kg) led to significant decrease in the number of Iba1 positive cells in dorsal root ganglia (similar to wild type levels) when compared to untreated Fabry controls [&lt;ulink linkID="1966172" linkType="Reference"&gt;1966172&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In April 2017,  preclinical data were reported. Fabry mice received pegunigalsidase alfa (1 mg/kg) or Fabrazyme and Replagal at the approved clinical doses (1 and 0.2 mg/kg, respectively) and were compared with untreated Fabry mice and wild type (healthy) mice as controls. For 3 months, bi-weekly iv infusions were administered. A 53% reduction in the number of Iba1 spots, a marker for inflammation of the peripheral sensory nerves system was observed in Fabry mice treated with pegunigalsidase alfa compared with untreated Fabry controls and the levels of Iba1 in the pegunigalsidase alfa-treated mice reached the levels of the healthy mice. Treatment of Fabry mice with pegunigalsidase alfa attenuated the progression of small fiber neuropathy compared with currently approved enzyme replacement therapies in Fabry mice and in untreated Fabry mice [&lt;ulink linkID="1918649" linkType="Reference"&gt;1918649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2017, preclinical data were presented at the 13th Annual Lysosomal Disease Network WORLD Symposium in San Diego, CA. In plasma, pegunigalsidase alfa had prolonged in-vitro stability, and following 10 days of incubation under lysosomal-like conditions, pegunigalsidase alfa maintained over 80% activity. In PRX-102 pharmacokinetic profile of male Fabry mice, an increased t1/2 of 581 minutes was observed [&lt;ulink linkID="1901594" linkType="Reference"&gt;1901594&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, preclinical data were presented at the 10th Annual World Symposium of the Lysosomal Disease Network in San Diego, CA. In cells from patients with Fabry disease, pegunigalsidase alfa was localized in the lysosome and showed higher stability in the lysosome and plasma than commercially available enzyme therapies [&lt;ulink linkID="1528551" linkType="Reference"&gt;1528551&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2010, the drug had shown promising results in an animal knock-out model [&lt;ulink linkID="1100125" linkType="Reference"&gt;1100125&lt;/ulink&gt;]. In January 2011, preclinical data  were presented. Pegunigalsidase alfa showed preliminary efficacy in an animal model of Fabry disease, and the modified version of the enzyme had improved activity and bioavailability and lower immunogenicity  [&lt;ulink linkID="1161905" linkType="Reference"&gt;1161905&lt;/ulink&gt;]. In January 2014, similar data were presented at the 32nd Annual JPMorgan Healthcare Conference in San Francisco, CA. There were also improved circulatory half-lives, with pegunigalsidase alfa reaching 581 min compared to 13 min with commercially available treatments. In vivo, the compound had higher active levels in heart and kidney over time in Fabry mice after a single injection compared to Replagal [&lt;ulink linkID="1516870" linkType="Reference"&gt;1516870&lt;/ulink&gt;]. In February 2014, similar preclinical data were presented at the 10th Annual World Symposium of the Lysosomal Disease Network in San Diego, CA [&lt;ulink linkID="1528551" linkType="Reference"&gt;1528551&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2018, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for treatment of Fabry disease [&lt;ulink linkID="2062871" linkType="Reference"&gt;2062871&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-24T00:00:00.000Z</StatusDate><Source id="2056785" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="PY">Paraguay</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="PY">Paraguay</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-18T00:00:00.000Z</StatusDate><Source id="1972338" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-24T00:00:00.000Z</StatusDate><Source id="2056785" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-12-31T00:00:00.000Z</StatusDate><Source id="889818" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-08T00:00:00.000Z</StatusDate><Source id="1329252" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-08T00:00:00.000Z</StatusDate><Source id="1329252" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-24T00:00:00.000Z</StatusDate><Source id="1879431" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-24T00:00:00.000Z</StatusDate><Source id="1879431" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-24T00:00:00.000Z</StatusDate><Source id="1879431" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-08T00:00:00.000Z</StatusDate><Source id="1329252" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="PY">Paraguay</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-08T00:00:00.000Z</StatusDate><Source id="1329252" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-06T00:00:00.000Z</StatusDate><Source id="1769708" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="PY">Paraguay</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-06T00:00:00.000Z</StatusDate><Source id="1769708" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-06T00:00:00.000Z</StatusDate><Source id="1769708" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-06T00:00:00.000Z</StatusDate><Source id="1769708" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014359">Protalix BioTherapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="774">Fabry disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-06T00:00:00.000Z</StatusDate><Source id="1769708" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="1014359">Protalix BioTherapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="774">Fabry disease</Indication><AwardedIndication>Treatment of Fabry disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="4">Planned</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2020-03-31T00:00:00.000Z</MileStoneDate><Source id="2160319" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="15381">Chiesi Farmaceutici SpA</OwnerCompany><Country id="US">US</Country><Indication id="774">Fabry disease</Indication><AwardedIndication>Treatment of Fabry disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="4">Planned</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2020-03-31T00:00:00.000Z</MileStoneDate><Source id="2160319" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1014359">Protalix BioTherapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="774">Fabry disease</Indication><AwardedIndication>Treatment of Fabry disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-31T00:00:00.000Z</MileStoneDate><Source id="2001494" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1014359">Protalix BioTherapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="774">Fabry disease</Indication><AwardedIndication>Treatment of Fabry disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-12T00:00:00.000Z</MileStoneDate><Source id="1993871" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1014359">Protalix BioTherapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="774">Fabry disease</Indication><AwardedIndication>Treatment of Fabry disease </AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-31T00:00:00.000Z</MileStoneDate><Source id="1989960" type="PR"></Source></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1014359">Protalix BioTherapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="774">Fabry disease</Indication><AwardedIndication>Treatment of Fabry disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-27T00:00:00.000Z</MileStoneDate><Source id="2062871" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00119"><Name>Alpha-galactosidase</Name><SwissprotNumbers><Swissprot>O34645</Swissprot><Swissprot>P06280</Swissprot><Swissprot>P06720</Swissprot><Swissprot>P14749</Swissprot><Swissprot>P27756</Swissprot><Swissprot>P28351</Swissprot><Swissprot>P30877</Swissprot><Swissprot>P43467</Swissprot><Swissprot>P43469</Swissprot><Swissprot>P51569</Swissprot><Swissprot>Q42656</Swissprot><Swissprot>Q9FXT4</Swissprot><Swissprot>Q9URZ0</Swissprot><Swissprot>Q9UUZ4</Swissprot><Swissprot>Q9X4Y0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2165062" linkType="reference" linkID="2165062"&gt;2165062&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1014359">Protalix BioTherapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1019589">State Of Israel The Ministry Of Industry &amp; Trade The National Physical Laboratory</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22310">Israeli Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="127718" title="Israel Ministry of Industry and Trade to award Protalix with funding for prGCD, recombinant acetylcholinesterase and PRX-102 programs "></Deal><Deal id="130563" title="The Israeli Government to fund development of Protalix's early stage compounds"></Deal><Deal id="243473" title="Chiesi to develop and commercialise Protalix's PRX-102 for Fabry disease worldwide ex-US  "></Deal></Deals><PatentFamilies><PatentFamily id="2475652" number="WO-2004096978" title="Production of high mannose proteins in plant culture"></PatentFamily><PatentFamily id="2478970" number="WO-2011061736" title="Alkaline alpha galactosidase for the treatment of fabry disease"></PatentFamily><PatentFamily id="4122301" number="WO-2018127920" title="Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase"></PatentFamily><PatentFamily id="992613" number="WO-2008132743" title="Production of high-mannose proteins in plant culture"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Metabogal Ltd" id="1010912"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protalix BioTherapeutics Inc" id="1014359"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Weizmann Institute of Science" id="15489"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>